Precision oncology through liquid biopsies involves detecting circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) directly from a patient's blood sample to provide insights into the genetic makeup of tumors, enabling personalized treatment strategies.
Liquid biopsies address the limitations of traditional tissue biopsy methods by providing non-invasive, repeatable, and less invasive ways to monitor disease progression and therapeutic responses. They can detect early-stage cancers where tumors are too small or inaccessible for conventional biopsies.
Samples are collected via a simple blood draw. The blood is processed using advanced technologies such as size-based separation or magnetic beads to isolate CTCs and ctDNA. These isolated components are then analyzed for mutations, gene expression patterns, and other biomarkers relevant to cancer diagnosis and treatment response.
The manufacturing process involves developing and validating liquid biopsy assays, which include sample collection devices, isolation technologies, and analytical platforms. These components must be rigorously tested for accuracy, reproducibility, and clinical utility.
The build process includes designing the assay, optimizing sample preparation techniques, validating the detection methods, and ensuring compliance with regulatory standards. This involves extensive testing to ensure that the technology can accurately detect relevant biomarkers across different patient populations.
No companies curated for this tile yet.
Curated names only — none are invented. Use the link to find more.
Cost drivers only — no verified dollar figures are shown. Check live sources for prices.
Illustrative — search real, dated examples rather than trusting a generated story.
Live searches — we don't list papers we can't verify.
Live patent searches — filings are never listed from memory.
Verify against primary sources only.
Source: curated technology intelligence stream with tracked references.